Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2008-11-11
2011-11-08
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
08052972
ABSTRACT:
Antibodies against AILIM (also called ICOS and 8F4) were found to significantly suppress the onset of inflammatory bowel diseases (especially Crohn's disease and colitis (ulcerative colitis and such)), and exhibit a significant therapeutic effect against inflammatory bowel diseases.
REFERENCES:
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5747461 (1998-05-01), Markov
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6531505 (2003-03-01), Xu et al.
patent: 6803039 (2004-10-01), Tsuji et al.
patent: 7030225 (2006-04-01), Tamatani et al.
patent: 7045615 (2006-05-01), Tamatani et al.
patent: 7112655 (2006-09-01), Tamatani et al.
patent: 7125551 (2006-10-01), Kroczek
patent: 7132099 (2006-11-01), Kroczek
patent: 7166283 (2007-01-01), Tsuji et al.
patent: 7196175 (2007-03-01), Tamatani et al.
patent: 7217792 (2007-05-01), Tamatani et al.
patent: 7226909 (2007-06-01), Tamatani et al.
patent: 7247612 (2007-07-01), Tamatani et al.
patent: 7259147 (2007-08-01), Tamatani et al.
patent: 7259247 (2007-08-01), Kroczek
patent: 7279560 (2007-10-01), Tamatani et al.
patent: 7294473 (2007-11-01), Tamatani et al.
patent: 7438905 (2008-10-01), Suzuki et al.
patent: 7465444 (2008-12-01), Watanabe
patent: 2002/0151685 (2002-10-01), Tamatani et al.
patent: 2002/0156242 (2002-10-01), Tamatani et al.
patent: 2002/0164697 (2002-11-01), Coyle et al.
patent: 2003/0083472 (2003-05-01), Tamatani et al.
patent: 2004/0131608 (2004-07-01), Watanabe
patent: 2004/0229790 (2004-11-01), Tezuka et al.
patent: 2006/0140944 (2006-06-01), Yoshinaga et al.
patent: 752433 (1999-04-01), None
patent: 19821060 (1999-04-01), None
patent: 0 984 023 (2000-03-01), None
patent: 1 125 585 (2001-08-01), None
patent: 5-72204 (1993-03-01), None
patent: 11-228442 (1999-08-01), None
patent: 2000-154151 (2000-06-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 97/26912 (1997-07-01), None
patent: WO 98/11909 (1998-03-01), None
patent: WO 98/19706 (1998-05-01), None
patent: WO 98/37415 (1998-08-01), None
patent: WO 98/38216 (1998-09-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 99/15553 (1999-04-01), None
patent: WO 00/19988 (2000-04-01), None
patent: WO 00/46240 (2000-08-01), None
patent: WO 00/67788 (2000-11-01), None
patent: WO 01/08700 (2001-02-01), None
patent: WO 01/12658 (2001-02-01), None
patent: WO 01/15732 (2001-03-01), None
patent: WO 01/18022 (2001-03-01), None
patent: WO 01/21796 (2001-03-01), None
patent: WO 01/32675 (2001-05-01), None
patent: WO 02/44364 (2001-06-01), None
patent: WO 01/64704 (2001-09-01), None
patent: WO 01/87981 (2001-11-01), None
patent: WO 02/070010 (2002-09-01), None
patent: WO 02/076504 (2002-10-01), None
Carlesso et al., “Depletion of inducible co-stimulator (ICOS) bearing T cells inhibits expansion of T follicular helper cells (TFH) and prevents disease in a graft versus host mouse model of scleroderma” Poster Presentation, American College of Rheumatology, 2009 Annual Scientific Meeting, Oct. 19, 2009.
Carlesso et al., “Targeted depletion of inducible co-stimulator (ICOS) bearing I cells prevents disease in a graft versus host model of scleroderma” Poster Presentation, 9thInternational Conference on Systemic Lupus Erythematosus, Jun. 25, 2010.
Cook et al., “The human immunoglobulin VHrepertoire,”Immunology Today(1995) 16(5):237-42.
Faggioni et al., “Determination of the minimum anticipated biological level (MABEL) for an ADCC-enhanced inducible co-stimulator (ICOS) monoclonal antibody for the treatment of autoimmune diseases” Poster Presentation, Annual Congress of the European League Against Rheumatism, Jun. 2010.
Ghosh et al. “Ulcerative colitis” (2000) BMJ. 320(7242):1119-23.
Hanauer et al. “Management of Crohn's disease in adults” (2001) Am J Gastroenterol. 96(3):635-43.
Koh et al., “A screening method of SH2 domain ligands and blockers using a solid phase binding” (1997) Cancer Lett. 120(1):1-7.
Mendez et al. “Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice” (1997) Nat Genet. 15(2):146-56.
Mittereder et al., “ICOS is critical for follicular helper T cells (TFH)-mediated maintenance of germinal center B cells in non human primates” Poster Presentation, American College of Rheumatology, 2008 Annual Scientific Meeting, Oct. 28, 2008.
Mittereder, “ICOS is critical for T follicular helper cell-mediated maintenance of germinal center B cells in non-human primates” FASEB Summer Research Conference—Autoimmunity, Jul. 2, 2009.
Soderlind et al., “Domain libraries: Synthetic diversity for de novo design of antibody V-regions,”Gene(1995) 160(2):269-72.
Takai et al. “Epitope analysis and primary structures of variable regions of anti-human FcepsilonRI monoclonal antibodies, and expression of the chimeric antibodies fused with human constant regions” Biosci Biotechnol Biochem. (2000) 64(9):1856-67.
Taylor et al. “Unraveling Functions of ICOS Bearing T Cells: New Insights about Treating Autoimmune Disorders” Poster Presentation, Keystone Symposia on Tolerance and Autoimmunity, Feb. 21-26, 2010.
van der Merwe et al., “CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics,”Journal of Experimental Medicine(1997) 185(3):393-403.
Abbas, “T-cell stimulation: an abundance of B7s,” Nat Med. 5(12):1345-6 (1999).
Aicher et al., “Characterization of human inducible costimulator ligand expression and function,” J. of Immunology 164:4689-4696 (2000).
Akbari et al., “Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity,” Nature Medicine 8(9):1024-1032 (2002).
Andersen et al., “Allelic variation of the inducible costimulator (ICOS) gene: detection of polymorphisms, analysis of the promoter region, and extended haplotype estimation,” Tissue Antigens 61:276-285 (2003).
Ara et al., “Potent activity of soluble B7RP-1-FC in therapy of murine tumors in syngeneic hosts,” Int. J. Cancer 103:501-507 (2003).
Arimura et al., “A co-stimulatory molecule on activated T cells, H4/ICOS, delivers specific signals in Thcells and regulates their responses,” International Immunology 14(6):555-566 (2002).
Atwood T., Science 2000, 290:471-473.
Bajorath, “A molecular model of inducible costimulator protein and three-dimensional analysis of its relation to the CD28 family of T cell-specific costimulatory receptors,” J. Mol. Model 5:169-176 (1999).
Beier et al., “Induction, binding specificity and function of human ICOS,” Eur. J. Immunol. 30:3707-3717 (2000).
Bensimon et al., “Human lupus anti-DNA autoantibodies undergo essentially primary V kappa gene rearrangements,” EMBO J. 13(13):2951-62 (1994).
Bennett et al., “Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses” J. of Immunol. 170:711-718 (2003).
Bertram et al., “Role of ICOS versus CD28 in antiviral immunity,” Eur. J. Immunol. 32:3376-3385 (2002).
Biancone et al., “Lymphocyte costimulatory receptors in renal disease and transplantation,” J. Nephrol 15:7-16 (2002).
Bonhagen et al., “ICOS+Th cells produce distinct cytokines in different mucosal immune responses,” Eur. J. Immunol. 33:392-401 (2003).
Brodie et al., “LICOS, a primordial costimulatory ligand?” Current Biology 10(6):333-336 (2000).
Buonfiglio et al., “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas,” Eur. J. Immu
Fish & Richardson P.C.
Japan Tobacco Inc.
Ouspenski Ilia
LandOfFree
Remedies for inflammatory bowel diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Remedies for inflammatory bowel diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Remedies for inflammatory bowel diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4280639